HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Clinical trials for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA explained in plain language.
Never miss a new study
Get alerted when new HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA trials appear
Sign up with your email to follow new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare cholesterol disease: phase 3 drug trial launches
Disease control Recruiting nowThis study tests a new drug called zodasiran in people aged 12 and older with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. The goal is to see if the drug safely lowers LDL (bad) cholesterol over 12 months. Participa…
Matched conditions: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Worldwide HoFH data pool aims to unlock rare cholesterol disease secrets
Knowledge-focused Recruiting nowThis study is building a global database of health information from 1,000 people with homozygous familial hypercholesterolemia (HoFH), a rare inherited condition that causes extremely high cholesterol from birth. Researchers will collect de-identified medical data to better under…
Matched conditions: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated May 26, 2026 11:13 UTC
-
New registry aims to unlock secrets of rare cholesterol disease
Knowledge-focused Recruiting nowThis study creates a registry for up to 60 children and adults in the U.S. with homozygous familial hypercholesterolemia (hoFH), a rare genetic condition causing extremely high cholesterol from birth. Researchers will track participants' overall health and cholesterol buildup in …
Matched conditions: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Sponsor: The Rogosin Institute • Aim: Knowledge-focused
Last updated May 26, 2026 11:12 UTC